Arvinas at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

Arvinas brings 3 presentations to ENA 2026 in Barcelona. Its posters centre on combination studies of ARV-806, a PROTAC KRAS G12D degrader, in KRAS G12D-mutated models. ARV-806 is paired with chemotherapy in pancreatic cancer, with EGFR antibodies in colorectal cancer and with the RAS-ON multi-selective inhibitor daraxonrasib.

Organization	ENA 2026 Attendance
Arvinas New Haven, CT
arvinas.com Biotech Develops PROTAC protein degraders, including vepdegestrant and the KRAS G12D degrader ARV-806.	Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With Chemotherapy in KRAS G12D–Mutated Pancreatic Cancer Models Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies (mAbs) in KRAS G12D–Mutated Colorectal Cancer (CRC) Models Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With the RAS-ON Multi-Selective Inhibitor Daraxonrasib in KRAS G12D–Mutated Models Targeted agents

Organization

ENA 2026 Attendance

Arvinas

New Haven, CT

arvinas.com

Biotech

Develops PROTAC protein degraders, including vepdegestrant and the KRAS G12D degrader ARV-806.

Poster

Fri Nov 20
10:45–11:15am
1:30–3pm

Part of Poster session: Combination Therapies

Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With Chemotherapy in KRAS G12D–Mutated Pancreatic Cancer Models

Targeted agents